{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=5", "query": { "intervention": "Period C", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 881, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T03:00:00.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00968357", "title": "Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "SCV-07", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciClone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2009-09", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 16, "location_summary": "Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00968357" }, { "nct_id": "NCT03926624", "title": "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "DFP-10917", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cladribine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delta-Fly Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2019-11-22", "completion_date": "2026-01-07", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03926624" }, { "nct_id": "NCT04506905", "title": "Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 63, "start_date": "2020-08-28", "completion_date": "2022-03-22", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 6, "location_summary": "Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Oakland Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04506905" }, { "nct_id": "NCT02960230", "title": "H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Glioma", "Diffuse Midline Glioma, H3 K27M-Mutant" ], "interventions": [ { "name": "K27M peptide", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 50, "start_date": "2016-11-18", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 14, "location_summary": "San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02960230" }, { "nct_id": "NCT04435600", "title": "A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 139, "start_date": "2020-07-14", "completion_date": "2024-10-15", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435600" }, { "nct_id": "NCT01548651", "title": "Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2012-02", "completion_date": "2017-08-25", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01548651" }, { "nct_id": "NCT04909242", "title": "Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "DZD9008", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 78, "start_date": "2021-04-21", "completion_date": "2022-02-07", "has_results": false, "last_update_posted_date": "2022-06-02", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04909242" }, { "nct_id": "NCT07127705", "title": "Rapid Response of Stem Cells and Immune Cells for Efficacy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stem Cell Surveillance" ], "interventions": [ { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Chaga Mushroom", "type": "DIETARY_SUPPLEMENT" }, { "name": "Ginseng extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "Olive extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "Potassium Hydrogen Glucarate", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Natural Immune Systems Inc", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2025-05-21", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 1, "location_summary": "Klamath Falls, Oregon", "locations": [ { "city": "Klamath Falls", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07127705" }, { "nct_id": "NCT00713791", "title": "Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ZD4054", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 20, "start_date": "2008-06", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2010-11-15", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00713791" }, { "nct_id": "NCT01464450", "title": "Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics", "Bioavailability", "Healthy Participants" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 55, "start_date": "2011-10", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-10-27T03:00:00.805Z", "location_count": 1, "location_summary": "Neptune City, New Jersey", "locations": [ { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464450" } ] }